To determine if the changes in mitophagy biomarkers were affected by the biomarker profile and severity, we analyzed the differences in mitophagy proteins across six ATN profiles, classified by the positive (+) or negative (-) status of P-tau181 (T), and T-tau (N) in both AD patients (A+) and FTLD (A-) patients. The gene discussed is MAPT; the disease is Alzheimer disease.